These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16870084)

  • 21. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
    Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
    Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA; Candrilli SD; Davis KL
    Manag Care; 2011 Aug; 20(8):46-50, 53-5. PubMed ID: 21887993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
    Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
    Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.
    Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM
    Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
    Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
    Gani R; Griffin J; Kelly S; Rutten-van Mölken M
    Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
    Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
    Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of tiotropium in the prevention of exacerbations of COPD.
    Anzueto A; Miravitlles M
    Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology.
    Seemungal T; Stockley R; Calverley P; Hagan G; Wedzicha JA
    COPD; 2007 Sep; 4(3):177-83. PubMed ID: 17729060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tiotropium as new quality medication in the COPD management].
    Lubiński W; Płusa T
    Pol Merkur Lekarski; 2006 Jan; 20(115):5-7. PubMed ID: 16617725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A; Shah M; D'Souza AO; Bechtel B; Crater G; Dalal AA
    Respir Res; 2012 Feb; 13(1):15. PubMed ID: 22340019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
    Dalal AA; Petersen H; Simoni-Wastila L; Blanchette CM
    J Med Econ; 2009; 12(4):339-47. PubMed ID: 19827993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.